Skip to main content

MINI REVIEW article

Front. Oncol.
Sec. Skin Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1514578

LAG3 Immune Inhibitors: A Novel Strategy for Melanoma Treatment

Provisionally accepted
Renzheng Wu Renzheng Wu *Mingtang Zeng Mingtang Zeng Yuchen Zhang Yuchen Zhang *Jianping He Jianping He *
  • West China Hospital, Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

    Melanoma, a highly aggressive skin cancer, poses significant challenges in treatment, particularly for advanced or metastatic cases. While immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1, has transformed melanoma management, many patients experience limited responses or develop resistance, highlighting the need for new therapeutic strategies. Lymphocyte activation gene 3 (LAG-3) has emerged as a promising target in cancer immunotherapy. LAG-3 inhibitors have shown potential in restoring T cell functions and enhancing anti-tumor immunity, particularly when used in combination with existing ICIs. This review discusses the latest advancements in LAG-3 inhibition for advanced melanoma, emphasizing its role in overcoming resistance and improving patient outcomes.

    Keywords: Lymphocyte activation gene 3, immune checkpoint inhibitors, Melanoma, antitumor immunity, Clinical Trial

    Received: 21 Oct 2024; Accepted: 27 Nov 2024.

    Copyright: © 2024 Wu, Zeng, Zhang and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Renzheng Wu, West China Hospital, Sichuan University, Chengdu, China
    Yuchen Zhang, West China Hospital, Sichuan University, Chengdu, China
    Jianping He, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.